<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37253434</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1711</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Immunology and cell biology</Title><ISOAbbreviation>Immunol Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Cardiomyocyte-derived HMGB1 takes a protective role in CVB3-induced viral myocarditis via inhibiting cardiac apoptosis.</ArticleTitle><Pagination><StartPage>735</StartPage><EndPage>745</EndPage><MedlinePgn>735-745</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/imcb.12660</ELocationID><Abstract><AbstractText>Coxsackievirus B3 (CVB3)-induced viral myocarditis (VMC) is characterized by immune cell infiltration and myocardial damage. High mobility group box 1 (HMGB1) is a highly conserved nuclear DNA-binding protein that participates in DNA replication, transcriptional regulation, repair response and inflammatory response in different disease models. To investigate the exact function of HMGB1 in CVB3-induced VMC, we crossed Hmgb1-floxed (Hmgb1<sup>f/f</sup> ) mice with mice carrying a suitable Cre recombinase transgenic strain to achieve conditional inactivation of the Hmgb1 gene in a cardiomyocyte-specific manner and to establish myocarditis. In this study, we found that cardiomyocyte-specific Hmgb1-deficient (Hmgb1<sup>f/f</sup> Tg<sup>Cre/+</sup> ) mice exhibited exacerbated myocardial injury. Hmgb1-deficient cardiomyocytes may promote early apoptosis via the p53-mediated Bax mitochondrial pathway, as evidenced by the higher localization of p53 protein in the cytosol of Hmgb1-deficient cardiomyocytes upon CVB3 infection. Moreover, cardiomyocyte Hmgb1-deficient mice are more susceptible to cardiac dysfunction after infection. This study provides new insights into HMGB1 in VMC pathogenesis and a strategy for appropriate blocking of HMGB1 in the clinical treatment of VMC.</AbstractText><CopyrightInformation>© 2023 the Australian and New Zealand Society for Immunology, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Tianle</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Chunsheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Sidong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Immunol Cell Biol</MedlineTA><NlmUniqueID>8706300</NlmUniqueID><ISSNLinking>0818-9641</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024243" MajorTopicYN="Y">HMGB1 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="Y">Enterovirus B, Human</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyocyte</Keyword><Keyword MajorTopicYN="N">coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">high mobility group box 1</Keyword><Keyword MajorTopicYN="N">p53 translocationviral myocarditis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37253434</ArticleId><ArticleId IdType="doi">10.1111/imcb.12660</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Rivadeneyra L, Charo N, Kviatcovsky D, de la Barrera S, Gomez RM, Schattner M. Role of neutrophils in CVB3 infection and viral myocarditis. J Mol Cell Cardiol 2018; 125: 149-161.</Citation></Reference><Reference><Citation>Klingel K, Stephan S, Sauter M, et al. Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J Virol 1996; 70: 8888-8895.</Citation></Reference><Reference><Citation>Bopegamage S, Borsanyiova M, Vargova A, Petrovicova A, Benkovicova M, Gomolcak P. Coxsackievirus infection of mice. I. Viral kinetics and histopathological changes in mice experimentally infected with coxsackieviruses B3 and B4 by oral route. Acta Virol 2003; 47: 245-251.</Citation></Reference><Reference><Citation>Garmaroudi FS, Marchant D, Hendry R, et al. Coxsackievirus B3 replication and pathogenesis. Future Microbiol 2015; 10: 629-653.</Citation></Reference><Reference><Citation>Maier RM, Pepper IL, Gerba CP. Environmental Microbiology. 2nd ed. Amsterdam, Boston: Elsevier/Academic Press; 2009.</Citation></Reference><Reference><Citation>Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 2008; 3: 127-155.</Citation></Reference><Reference><Citation>Dong Y, Ming B, Dong L. The role of HMGB1 in rheumatic diseases. Front Immunol 2022; 13: 815257.</Citation></Reference><Reference><Citation>Calogero S, Grassi F, Aguzzi A, et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999; 22: 276-280.</Citation></Reference><Reference><Citation>Yu Y, Yu Y, Liu M, et al. Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by suppression of HMGB1/RAGE/NF-κB pathway. SpringerPlus 2016; 5: 215.</Citation></Reference><Reference><Citation>Yu Y, Shi H, Yu Y, et al. Inhibition of calpain alleviates coxsackievirus B3-induced myocarditis through suppressing the canonical NLRP3 inflammasome/caspase-1-mediated and noncanonical caspase-11-mediated pyroptosis pathways. Am J Transl Res 2020; 12: 1954-1964.</Citation></Reference><Reference><Citation>Kim H, Mun D, Kang JY, Lee SH, Yun N, Joung B. Improved cardiac-specific delivery of RAGE siRNA within small extracellular vesicles engineered to express intense cardiac targeting peptide attenuates myocarditis. Mol Ther Nucleic Acids 2021; 24: 1024-1032.</Citation></Reference><Reference><Citation>Funayama A, Shishido T, Netsu S, et al. Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovasc Res 2013; 99: 657-664.</Citation></Reference><Reference><Citation>Hernandez-Pando R, Barrios-Payan J, Mata-Espinosa D, et al. The role of high mobility group box 1 protein (HMGB1) in the immunopathology of experimental pulmonary tuberculosis. PLoS One 2015; 10: e0133200.</Citation></Reference><Reference><Citation>Kitahara T, Takeishi Y, Harada M, et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 2008; 80: 40-46.</Citation></Reference><Reference><Citation>Wang X, Li Z, Bai Y, et al. A small molecule binding HMGB1 inhibits caspase-11-mediated lethality in sepsis. Cell Death Dis 2021; 12 402.</Citation></Reference><Reference><Citation>Gajic D, Despotovic S, Koprivica I, Miljkovic D, Saksida T. Ethyl pyruvate ameliorates experimental autoimmune myocarditis. Biomolecules 2021; 11: 1768.</Citation></Reference><Reference><Citation>Huebener P, Gwak GY, Pradere JP, et al. High-mobility group box 1 is dispensable for autophagy, mitochondrial quality control, and organ function in vivo. Cell Metab 2014; 19: 539-547.</Citation></Reference><Reference><Citation>Rowell JP, Simpson KL, Stott K, Watson M, Thomas JO. HMGB1-facilitated p53 DNA binding occurs via HMG-box/p53 transactivation domain interaction, regulated by the acidic tail. Structure 2012; 20: 2014-2024.</Citation></Reference><Reference><Citation>Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014.</Citation></Reference><Reference><Citation>Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.</Citation></Reference><Reference><Citation>Abe N, Ebina T, Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol 1982; 26: 535-539.</Citation></Reference><Reference><Citation>Faridvand Y, Nozari S, Vahedian V, et al. Nrf2 activation and down-regulation of HMGB1 and MyD88 expression by amnion membrane extracts in response to the hypoxia-induced injury in cardiac H9c2 cells. Biomed Pharmacother 2019; 109: 360-368.</Citation></Reference><Reference><Citation>Deng M, Tang Y, Li W, et al. The endotoxin delivery protein HMGB1 mediates Caspase-11-dependent lethality in sepsis. Immunity 2018; 49: 740-753.e747.</Citation></Reference><Reference><Citation>Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.</Citation></Reference><Reference><Citation>Celona B, Weiner A, Di Felice F, et al. Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol 2011; 9: e1001086.</Citation></Reference><Reference><Citation>Narumi T, Shishido T, Otaki Y, et al. High-mobility group box 1-mediated heat shock protein beta 1 expression attenuates mitochondrial dysfunction and apoptosis. J Mol Cell Cardiol 2015; 82: 1-12.</Citation></Reference><Reference><Citation>Livesey KM, Kang R, Vernon P, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res 2012; 72: 1996-2005.</Citation></Reference><Reference><Citation>Sun R, Sun S, Zhang Y, et al. PCV2 induces reactive oxygen species to promote nucleocytoplasmic translocation of the viral DNA binding protein HMGB1 to enhance its replication. J Virol 2020; 94: e00238-20.</Citation></Reference><Reference><Citation>Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005; 309: 1732-1735.</Citation></Reference><Reference><Citation>Wallach D, Kovalenko A. Keeping inflammation at bay. Elife 2014; 3: e02583.</Citation></Reference><Reference><Citation>Che Y, Tian Y, Chen R, Xia L, Liu F, Su Z. IL-22 ameliorated cardiomyocyte apoptosis in cardiac ischemia/reperfusion injury by blocking mitochondrial membrane potential decrease, inhibiting ROS and cytochrome C. Biochim Biophys Acta Mol Basis Dis 2021; 1867: 166171.</Citation></Reference><Reference><Citation>Xiang M, Lu Y, Xin L, et al. Role of oxidative stress in reperfusion following myocardial ischemia and its treatments. Oxid Med Cell Longev 2021; 2021: 6614009.</Citation></Reference><Reference><Citation>Banerjee I, Fuseler JW, Price RL, Borg TK, Baudino TA. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 2007; 293: H1883-H1891.</Citation></Reference><Reference><Citation>Zhou P, Pu WT. Recounting cardiac cellular composition. Circ Res 2016; 118: 368-370.</Citation></Reference><Reference><Citation>Li Y, Ma J, Zhu H, et al. Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes 2011; 60: 2985-2994.</Citation></Reference><Reference><Citation>Su N, Yue Y, Xiong S. Monocytic myeloid-derived suppressor cells from females, but not males, alleviate CVB3-induced myocarditis by increasing regulatory and CD4+IL-10+ T cells. Sci Rep 2016; 6: 22658.</Citation></Reference><Reference><Citation>Ehler E, Moore-Morris T, Lange S. Isolation and culture of neonatal mouse cardiomyocytes. J Vis Exp 2013; 79: 50154.</Citation></Reference><Reference><Citation>Zeng Y, Du WW, Wu Y, et al. A circular RNA binds to and activates AKT phosphorylation and nuclear localization reducing apoptosis and enhancing cardiac repair. Theranostics 2017; 7: 3842-3855.</Citation></Reference><Reference><Citation>Wu X, Meng Y, Wang C, Yue Y, Dong C, Xiong S. Semaphorin7A aggravates coxsackievirusB3-induced viral myocarditis by increasing alpha1beta1-integrin macrophages and subsequent enhanced inflammatory response. J Mol Cell Cardiol 2018; 114: 48-57.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>